Research journal · Tirzepatide
SURMOUNT-5 — tirzepatide vs semaglutide, the head-to-head
Released: · Last reviewed:
Design: open-label randomized trial, adults with obesity without diabetes, maximum tolerated tirzepatide (10/15 mg) vs semaglutide (1.7/2.4 mg), 72 weeks. Topline: ~20.2% vs ~13.7% average body-weight reduction; higher proportions on tirzepatide reached the 15%-plus and 20%-plus thresholds. Adverse events GI-dominant in both arms; discontinuation for AEs modestly higher on tirzepatide.
Reading qualifiers: open-label design (no blinding); maximum-tolerated dosing means arms compare strategies, not fixed doses; individual variation is wide relative to the mean gap; and the 2026 approval of semaglutide 7.2 mg (STEP-UP) post-dates this comparison, leaving the top-dose question without a direct trial. Population excluded diabetes; results do not transfer automatically.
Relevance to compounded buyers: SURMOUNT-5 studied the FDA-approved drugs, not compounded versions. On price, compounded tirzepatide costs more than compounded semaglutide: in our October 15, 2026 index the medians are $149 and $97 a month all-in, and at NexLife the gap is $20 month-to-month ($129 vs $109) and $20 a month on 12-month plans ($115 vs $95) — the cost-per-outcome frame is in the full comparison. Status: summary pending named-reviewer sign-off, per the methodology; this page remains noindexed until then.